HHLA2 (HBM-1020 Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA891555MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q9UM44

Alternative Names

Anti-B7H7 monoclonal antibody - Harbour BioMed research-grade biosimilar; HBM 1020 research-grade biosimilar; HBM-1020 research-grade biosimilar ;HHLA2 antibody; HERV-H LTR-associating protein 2 antibody; Human endogenous retrovirus-H long terminal repeat-associating protein 2 antibody

Species Reactivity

Human

Immunogen

Recombinant Human HHLA2 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

3-4 weeks
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is a research-grade biosimilar to HBM-1020, designed for research targeting HHLA2 (Human Endogenous Retrovirus-H Long Repeat-Associating 2), also known as B7-H7 or B7-H5. HHLA2 is an immune checkpoint molecule belonging to the B7 family that functions as a co-inhibitory receptor, regulating T cell responses and modulating immune homeostasis. HHLA2 is expressed on antigen-presenting cells and various tumor types, where it interacts with receptors including TMIGD2 and KIR3DL3 to suppress T cell activation and proliferation. Aberrant HHLA2 expression has been implicated in immune evasion mechanisms across multiple cancers, including breast cancer, lung cancer, pancreatic cancer, and melanoma, making it an emerging target in immuno-oncology research.

HBM-1020 is a reference antibody developed to investigate HHLA2-mediated immune regulation and its role in tumor immunology. This biosimilar enables researchers to explore HHLA2 signaling pathways, evaluate its contribution to the tumor microenvironment, and assess potential therapeutic strategies targeting this immune checkpoint. The antibody serves as a valuable tool for advancing understanding of cancer immune evasion and developing novel immunotherapeutic approaches.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade.

Gene References into Functions

HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases. PMID:27531281
HHLA2 was not detected in most of normal lung tissue but expressed in 66% of NSCLC across different subtypes. In particular, EGFR-mutated NSCLC was significantly associated with higher tumor HHLA2 expression in both discovery and validation lung cancer cohorts. HHLA2 is widely expressed in NSCLC and is associated with EGFR mutation and high TILs in lung adenocarcinoma. PMID:27553831
Low B7-H5 expression is associated with pancreatic adenocarcinomas. PMID:25519928
The HHLA2 pathway represents a novel immunosuppressive mechanism within the tumor microenvironment. PMID:25549724
B7 homologue 5 (B7-H5), was identified as a specific ligand for CD28H PMID:23784006
Data indicate that HHLA2 protein was predominantly found on cell membranes with some in the cytoplasm. PMID:23716685

Hide All

Subcellular Location

Membrane; Single-pass type I membrane protein.

Tissue Specificity

Expressed at high levels in colon, kidney, testis, lung and pancreas, and at lower levels in small intestine, liver and skeletal muscle. In immune cells, highly expressed in B-cells, dendritic cells and macrophages. Not detected in T-cells.

Database Links

HGNC: 4905

UNIGENE: Hs.225968

KEGG: hsa:11148

STRING: 9606.ENSP00000350402

OMIM: 604371

Promotions